Provided by Tiger Trade Technology Pte. Ltd.

Tonix Pharmaceuticals

7.55
-0.1450-1.88%
Post-market: 7.550.00000.00%16:28 EDT
Volume:702.52K
Turnover:5.34M
Market Cap:129.49M
PE:-0.60
High:7.79
Open:7.70
Low:7.42
Close:7.70
52wk High:24.49
52wk Low:7.42
Shares:17.15M
Float Shares:14.99M
Volume Ratio:0.67
T/O Rate:4.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.4882
EPS(LYR):-14.5713
ROE:-81.82%
ROA:-46.84%
PB:0.58
PE(LYR):-0.52

Loading ...

Tonix Q2 Revenue Rises Sharply on Tonmya Launch

Reuters
·
Aug 10

Tonix Q2 FY26 Net Loss Narrows to $40.55 Million; Product Revenue Rises to $13.54 Million

Reuters
·
Aug 10

Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate

Benzinga Earnings
·
Aug 10

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

THOMSON REUTERS
·
Aug 10

Tonix Pharmaceuticals Q2 Net Income USD -40.552 Million

THOMSON REUTERS
·
Aug 10

Tonix Pharmaceuticals Holding Corp. Expected to Post a Loss of $2.70 a Share - Earnings Preview

Reuters
·
Aug 08

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Aug 05

Tonix Publishes Investor Deck Highlighting Tonmya Fibromyalgia Launch and Pipeline Updates

Reuters
·
Aug 04

Tonix Pharmaceuticals receives Type C meeting minutes from FDA for TNX-4800

TIPRANKS
·
Aug 03

Tonix Plans Adaptive Phase 2 Trial of TNX-4800 Antibody to Prevent Lyme Disease, Targets Q1 2027 Start

Reuters
·
Aug 03

Tonix Pharmaceuticals - Plans to Start Phase 2 Tnx-4800 Study in Q1 2027

THOMSON REUTERS
·
Aug 03

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of Tnx-4800, a Human, Anti-Ospa Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

THOMSON REUTERS
·
Aug 03

Tonix Pharmaceuticals - Majority of Enrollment Expected in 2028 Season, May Extend into 2029

THOMSON REUTERS
·
Aug 03

Tonix Pharmaceuticals Posts Investor Deck Focused on Tonmya Fibromyalgia Launch and Pipeline Updates

Reuters
·
Jul 28

Tonix Pharma to Report Q2 Results, Host Conference Call and Webcast

Reuters
·
Jul 27

Tonix Pharma CMO Gregory Sullivan to Retire Aug. 20

Reuters
·
Jul 22

Tonix Pharmaceuticals Publishes Investor Deck Highlighting Tonmya Fibromyalgia Launch Strategy

Reuters
·
Jul 20

Tonix Pharmaceuticals Investor Deck Spotlights Tonmya Fibromyalgia Launch and Late-stage Pipeline Plans

Reuters
·
Jul 17

Tonix Publishes Journal of Virology Study Showing 2022 Mpox Clade Iib up to 100,000-fold Less Virulent than 2003 Clade Iia

Reuters
·
Jul 15

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

GlobeNewswire
·
Jul 15